Internal Performance Data
Trenchant’s AutoCell™ addresses the most critical bottlenecks in cell therapy production: cell loss and operator-dependent processing. Internal testing evaluated performance across core unit operations including:
Washing
T-cell selection and activation
Viral transduction
Study Design
Five fresh apheresis collections from healthy volunteer donors were processed on the Trenchant prototype within 36 hours of collection. All processing was performed using Trenchant proprietary buffers, microbubble protocols, and closed processing cassettes.
Performance Results
Apheresis Wash Recovery
97.2% ± 2.3%
Mean T-cell recovery
99.1% ± 0.8%
Mean viability retention
Single-step T-cell Selection & Activation Recovery
95.3% ± 2.0%
Mean T-cell recovery
98.8% ± 0.4%
Mean T-cell purity
98.0% ± 1.1%
Mean viability retention
Lentiviral Transduction Efficiency
74.1% ± 5.2%
Mean GFP expression
Conclusions
Internal testing demonstrates that the AutoCell meets or exceeds industry performance targets across all critical unit operations. High cell recovery, purity, and viability are maintained throughout an automated workflow, resulting in substantially higher cumulative yield of gene-modified cells than conventional approaches.